Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

Acute erythroid leukemia (AEL) is a high-risk leukemia of poorly understood genetic basis,
with controversy regarding diagnosis in the spectrum of myelodysplasia and myeloid …

PURPOSE A previous study by the International Berlin-Frankfurt-Münster Study Group (I-
BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic …

Acute myeloid leukemia (AML) accounts for 25% of pediatric leukemia and affects
approximately 180 patients annually in Japan. The treatment outcome for pediatric AML has …

Recent advances in the genetic understanding of acute myeloid leukemia (AML) have
improved clinical outcomes in pediatric patients. However,∼ 40% of patients with pediatric …

Simple Summary Owing to the 40-year worldwide efforts for improving diagnosis and
therapy for acute myeloid leukemia (AML), the second most common type of leukemia in …

Objectives As the prognosis of relapsed/refractory (R/R) acute myeloid leukaemia (AML)
remains poor, novel treatment strategies are urgently needed. Clinical trials have shown that …

Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia
(AML) ultimately die from the disease. Few prognostic markers have been identified. We …

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease that requires a
multifaceted treatment approach. Although outcomes for low‐risk AML have improved …